HCA Healthcare (HCA) Margin Improvement To 9% Tests Bearish Leverage Concerns

HCA Healthcare (HCA) has opened 2026 earnings season with Q1 results that cap a run of rising top line and EPS, with Q4 2025 revenue at about US$19.5b, basic EPS of US$8.14 and net income of US$1.88b, supported by trailing twelve month EPS of US$28.70 on revenue of roughly US$75.6b and net income of US$6.78b. Over recent quarters the company has seen revenue move from US$17.5b in Q3 2024 to US$19.5b in Q4 2025, while quarterly basic EPS shifted from US$4.95 to US$8.14. This sets expectations around how durable current profitability and margins look as investors weigh the latest print.

See our full analysis for HCA Healthcare.

With the headline numbers on the table, the next step is to see how these results compare with the most common stories around HCA Healthcare’s growth drivers, risks and longer term earnings profile.

See what the community is saying about HCA Healthcare

Margins steady at 9% on US$75.6b revenue

• Over the last 12 months, HCA generated about US$75.6b of revenue and US$6.8b of net income, which works out to a 9% net margin versus 8.2% a year earlier.
• Analysts’ consensus view points to slightly softer margins ahead, with profit margin assumptions easing from the current 9% to around 8.7%, even though recent volume growth and cost controls have supported earnings.
  • That creates a gap between solid trailing earnings growth of 17.8% and the more modest earnings growth forecast of about 4.5% a year, which investors will weigh against the margin outlook.
  • Comments about broad-based volume growth and improved operating efficiency sit alongside concerns about higher professional fees and changing Medicaid volumes, which directly tie back to how sustainable that 9% margin looks.

Earnings growth outpacing revenue trend

• On a trailing 12 month basis, earnings grew 17.8% while revenue is modeled to grow at roughly 5% a year and earnings at about 4.5% a year going forward.
• The bullish narrative leans on broad volume gains and capacity investments to support that gap between past and forecast growth, but the numbers also highlight where optimism is being tested.
  • Forecast revenue growth of about 5% a year lines up with expectations for continued demand across inpatient admissions and other services, yet the step down from 17.8% earnings growth to about 4.5% forecast growth shows that recent strength is not simply being projected forward.
  • Analysts expecting earnings of about US$7.6b by 2029, up from roughly US$6.8b today, are effectively assuming steady but not explosive expansion, which is a more measured version of the bullish story.

On these numbers, bulls argue there is still room for HCA if volume growth and efficiency gains hold up over time. However, the forecasts show that future earnings power is expected to build more gradually than the last year might suggest, so it pays to see how the optimistic case is framed in detail 🐂 HCA Healthcare Bull Case.

Valuation gap versus DCF and targets

• At a current share price of US$432.46, HCA trades on a P/E of 14.3x versus peer and industry averages of 17.1x and 24.1x, sits well below a stated DCF fair value of about US$890.11, and below an analyst price target of roughly US$542.67.
• Bears focus less on these valuation gaps and more on balance sheet quality, arguing that high debt and negative shareholders’ equity are key reasons the market might keep discounting the stock despite cheaper multiples.
  • The flagged negative shareholders’ equity and high leverage give critics concrete balance sheet figures to point to when explaining why a model suggests around 51.4% upside to DCF fair value while the market price still sits far below that level.
  • At the same time, analysts citing implied upside of about 25.5% from US$432.46 to around US$542.67 show that many forecasts still see room above today’s price, which stands in contrast to the cautious focus on leverage risk.

If you want to see how concerns around debt and equity sit alongside this valuation gap and what the more cautious investors are pointing to in detail, it is worth reading the full bear case 🐻 HCA Healthcare Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for HCA Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

If the mix of risks and rewards in this story feels finely balanced, move quickly to review the underlying data and form your own view with 5 key rewards and 3 important warning signs

Explore Alternatives

HCA Healthcare combines a 9% net margin and lower P/E with high leverage, negative shareholders’ equity and earnings growth forecasts that sit well below recent results.

If balance sheet pressure and measured earnings expectations make you cautious here, compare that risk profile with companies highlighted in the solid balance sheet and fundamentals stocks screener (42 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com